Co-Founder & Cbo
CurrentLeading corporate development to build the world's most advanced AI-enabled therapeutic discovery and development platform targeting root causes of aging. In the first 3 years we generated 4 small molecule programs each with "pipeline in a pill" economic potential for Parkinson's disease, heart failure, and more that if successful could deliver over $1 trillion of commercial value.